Chronic kidney disease and cellular calcium homeostasis

Czech version

Authors: I. Lajdová; A. Okša; A. Spustová; R. Dzúrik
Authors‘ workplace: Ústav farmakológie, klinickej a experimentálnej farmakológie Lekárskej fakulty SZU Bratislava, Slovenská republika, prednosta prof. MUDr. Jozef Holomáň, CSc.
Published in: Vnitř Lék 2012; 58(7 a 8): 48-53
Category: 80th Birthday MUDr. Miroslav Mydlík, DrSc.

Overview

Free intracellular calcium represents a critical signaling mediator in a number of biological systems. Calcium cations (Ca²⁺) are an important ubiquitous messenger, controlling a broad range of cellular processes. Free cytosolic calcium concentration ([Ca²⁺]_i) is controlled by mechanisms that regulate Ca²⁺ entry from the extracellular space and Ca²⁺ release from intracellular stores, and by the activity of ATP-dependent Ca²⁺ pumps and antiporters that move Ca²⁺ back into stores or out of cells. Chronic kidney disease is associated with a significant elevation in [Ca²⁺]_i which is toxic to the cells and may be responsible for a multiple organ dysfunction. Disturbances in cellular calcium homeostasis in patients with chronic kidney disease represent a complex process. Our studies elucidate pathophysiological mechanisms of altered cellular calcium homeostasis in the peripheral blood mononuclear cells which represent the model of nonexcitable cells in patients with chronic kidney disease. The results demonstrate that [Ca²⁺]_i is significantly increased in peripheral blood mononuclear cells already in early stages of chronic kidney disease. The calcium concentration of intracellular stores and the capacitative calcium entry into the cells of these patients are significantly higher in comparison with healthy volunteers. Also the pore-forming P2X₇ receptors participate in increased [Ca²⁺]_i in peripheral blood mononuclear cells of patients with chronic kidney disease. An altered P2X₇ receptor function and increased P2X₇ receptor expression may contribute to the complex disturbances in intracellular calcium homeostasis in chronic kidney disease. On the other hand, the activity of plasmatic membrane Ca²⁺-ATPases which is responsible for removing excessive calcium out of the cell, was found to be decreased by 25 % when compared to healthy subjects. It means that not only the mechanisms of entry, but also of the removal are impaired by the disease. All these alterations in calcium signaling are contributing very likely to the elevated [Ca²⁺]_i from early stages of chronic kidney disease.

Key words:
intracelullar calcium – chronic kidney disease – calcium signaling and regulation

Sources

1. Donnadieu E, Bismuth G, Trautmann A. Calcium fluxes in T lymphocytes. J Biol Chem 1992; 267: 25864–25872.

2. Kárpáti I, Seres I, Mátyus J et al. Which parameters affect cytosolic free calcium in polymorphonuclear leukocytes of haemodialysis patients? Nephrol Dial Transplant 2001; 16: 1409–1415.

3. Koorts AM, Kruger MC, Potgieter CD et al. Intracellular free calcium in the neutrophils of maintenance haemodialysis patients. Clin Physiol 2002; 22: 285–294.

4. Berridge MJ. Elementary and global aspects of calcium signalling. J Exp Biol 1997; 200: 315–319.

5. Lajdová I, Spustová V, Okša A et al. Intracellular calcium homeostasis in patients with early stages of chronic kidney disease: effects of vitamin D3 supplementation. Nephrol Dial Transplant 2009; 24: 3376–3381.

6. Parekh AB, Putney AB Jr. Store-operated calcium channels. Physiol Rev 2005; 85: 757–810.

7. Lewis RS. Calcium signaling mechanisms in T lymphocytes. Ann Rev Immunol 2001; 19: 497–521.

8. Mattson MP, Chan SL. Neuronal and glial calcium signaling in Alzheimer’s disease. Cell Calcium 2003; 34: 385–397.

9. Partiseti M, Ledeisit F, Hivroz C et al. The calcium current activated by T cell receptor and store-depletion in human lymhocytes is absent in a primary immunodeficiency. J Biol Chem 1994; 269: 32327–32335.

10. Raraty M, Ward J, Erdemli G et al. Calcium-dependent enzyme activation and vacuole formation in the apical granular region of pancreatic acinar cells. Proc Natl Acad Sci (USA) 2000; 97: 13126–13131.

11. Somlo S, Ehrlich B. Human disease: calcium signaling in polycystic kidney disease. Curr Biol 2001; 11: R356–R360.

12. Gelfand EW, Cheung RK, Grinstein S et al. Characterization of the role for calcium influx in mitogen-induced triggering of human T cells. Identification of calcium-dependent and calcium-independent signals. Eur J Immunol 1986; 16: 907–912.

13. Kotturi FM, Douglas AC, Lee JC et al. Identification and functional characterization of voltage-dependent calcium channels in T lymphocytes. J Biol Chem 2003; 278: 46949–46960.

14. Baricordi OR, Ferrari D, Melchiorri L et al. An ATP-activated channel is involved in mitogenic stimulation of human lymphocytes. Blood 1996; 87: 682–690.

15. Ralevic V, Burnstock G. Receptors for purines and pyrimidines. Pharmacol Rev 1998; 50: 413–492.

16. North AR. Molecular physiology of P2X receptors. Physiol Rev 2002; 82: 1013–1067.

17. Vonend O, Turner CM, Chan ChM et al. Glomerular expression of ATP-sensitive P2X₇ receptor on diabetic and hypertensive rat models. Kidney Int 2004; 66: 157–166.

18. Jorgensen NR, Henriksen Z, Sorensen OH et al. Intracellular calcium signaling occurs between human osteoblasts and osteoclasts and requires activation of osteoclast P2X₇ receptors. J Biol Chem 2002; 277: 7574–7580.

19. Di Virgilio F, Sollini A. P2 receptors: new potential players in atherosclerosis. British J Pharm 2002; 135: 831–842.

20. Gu BJ, Zhang WY, Bendall LJ et al. Expression of P2X₇ purinoceptors on human lymphocytes and monocytes: evidence for nonfunctional P2X₇ receptors. Am J Physiol Cell Physiol 2000; 279: C1189–C1197.

21. Lajdova I, Oksa A, Chorvat D Jr et al. Purinergic P2X₇ receptors participate in disturbed intracellular calcium homeostasis in peripheral blood mononuclear cells of patients with chronic kidney disease. Kidney Blood Press Res 2012; 35: 48–57.

22. Al-Shukaili A, Al-Kaabi J, Hassan B. A comparative study of interleukin-1β production and P2X₇ expression after Atp stimulation by peripheral blood mononuclear cells isolated from rheumatoid arthritis patients and normal healthy controls. Inflammation 2008; 31: 84–90.

23. Franco-Martinez S, Nino-Moreno P, Bernal--Silva S et al. Expression and function of the purinergic receptor P2X₇ in patients with pulmonary tuberculosis. Clin Exp Immunol 2006; 146: 253–261.

24. Kaderjakova Z, Lajdova I, Horvathova M et al. Effect of chronic kidney disease on blood cells membrane properties. Bioelectrochemistry 2012; doi:10.1016/j.bioelechem.2012.02. 006.

25. Gafter U, Malachi T, Barak H et al. Red blood cell calcium homeostasis in patients with end-stage renal disease. J Lab Clin Med 1989; 114: 221–231.

26. Polak-Jonkisz D, Purzyc L, Laszki-Szcza K et al. The endogenous modulators of Ca2+-Mg2+-dependent ATPase in children with chronic kidney disease (CKD). Nephrol Dial Transplant 2010; 25: 438–444.

27. Massry SG. Is parathyroid hormone a uremic toxin? Nephron 1977; 19: 125–130.

28. Rostand SG, Sanders C, Kirk KA et al. Myocardial calcification and cardiac dysfunction in chronic renal failure. Am J Med 1988; 85: 651–657.

29. Raine AEG, Bedford L, Simpson AWM et al. Hyperparathyroidism, platelet intracellular free calcium and hypertension in chronic renal failure. Kidney Int 1993; 43: 700–705.

30. Kraikipanitch S, Linderman RD, Yoenice AA et al. The effect of azotemia and myocardial accumulation of calcium. Miner Electrol Metab 1978; 1: 12–20.

31. Massry SG, Fadda GZ. Chronic renal failure is a state of cellular calcium toxicity. Am J Kidney Dis 1993; 21: 81–86.

32. Ori Y, Korzets A, Malachi T et al. Impaired lymphocyte calcium metabolism in end-stage renal disease: enhanced influx, decreased efflux, and reduced response to mitogen. J Lab Clin Med 1999; 133: 391–400.

33. Deicher R, Kirsch B, Müllner M et al. Impact of parathyroidectomy on neutrophil cytosolic calcium in chronic kidney disease patients: a prospective parallel group trial. J Int Med 2005; 258: 67–76.